$PTX - News: Marsha Stanton, Ph.D., RN, Pernix Therapeutics Executive Director of Medical and Government Affairs, Awarded Prestigious Pain Management Advocacy Award from the American Society for Pain Management Nursing(R)
Pernix Therapeutics Holdings, Inc. (NASDAQ
TX), a specialty pharmaceutical company with a focus on Pain and CNS conditions, today announced that Marsha Stanton, Ph.D., RN, Executive Director of Medical and Government Affairs, was awarded the prestigious Pain Management Advocacy Award from the American Society for Pain Management Nursing(R) (ASPMN) at the 2016 ASPMN National Conference, which was held in Louisville, KY, from September 7-10, 2016.
"We are proud of Dr. Stanton's recognition at the ASPMN national conference, and are very pleased to have someone of her caliber as a member of the Pernix Therapeutics team," said John Sedor, Chairman and CEO of Pernix Therapeutics.
Nominees for the Pain Management Advocacy Award must demonstrate leadership and outstanding contributions which have influenced public perception, attitudes, and awareness of pain and its management through public education, governmental reform, and/or media exposure compatible with the ASPMN mission and goals.
Dr. Stanton is nationally recognized for her extensive work in pain management, including clinical practice, public policy and patient education. She is a registered nurse, and obtained her Master of Science in Health & Human Services from Columbia Pacific University and a Ph.D. in Health Education from Glendale University.
About Pernix Therapeutics
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and pain management, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its two Pernix sales forces and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.
To learn more about Pernix Therapeutics, visit www.pernixtx.com.
Zohydro ER is a registered trademark of Pernix Therapeutics Holdings, Inc. BeadTek(TM) is a trademark used by Pernix under license.
Pernix Therapeutics Holdings, Inc. (NASDAQ
TX), a specialty pharmaceutical company with a focus on Pain and CNS conditions, today announced that Marsha Stanton, Ph.D., RN, Executive Director of Medical and Government Affairs, was awarded the prestigious Pain Management Advocacy Award from the American Society for Pain Management Nursing(R) (ASPMN) at the 2016 ASPMN National Conference, which was held in Louisville, KY, from September 7-10, 2016. "We are proud of Dr. Stanton's recognition at the ASPMN national conference, and are very pleased to have someone of her caliber as a member of the Pernix Therapeutics team," said John Sedor, Chairman and CEO of Pernix Therapeutics.
Nominees for the Pain Management Advocacy Award must demonstrate leadership and outstanding contributions which have influenced public perception, attitudes, and awareness of pain and its management through public education, governmental reform, and/or media exposure compatible with the ASPMN mission and goals.
Dr. Stanton is nationally recognized for her extensive work in pain management, including clinical practice, public policy and patient education. She is a registered nurse, and obtained her Master of Science in Health & Human Services from Columbia Pacific University and a Ph.D. in Health Education from Glendale University.
About Pernix Therapeutics
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and pain management, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its two Pernix sales forces and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.
To learn more about Pernix Therapeutics, visit www.pernixtx.com.
Zohydro ER is a registered trademark of Pernix Therapeutics Holdings, Inc. BeadTek(TM) is a trademark used by Pernix under license.
